Asia-Pacific Diffuse Large B-cell Lymphoma Therapeutics Market Study 2022

Asia-Pacific diffuse large b-cell lymphoma therapeutics Market is estimated to grow at a CAGR of 7.3% during the forecast period (2022-2029) to reach a market vale of USD  YY million by 2029.

Asia-Pacific is likely to emerge as the most promising regional market in the coming years owing to the factor such as strengthening economy and the improving healthcare infrastructure in this region are expected to act as the key driving force behind the growth of the market.

Lee et al. reported the subtype-specific statistical analysis of diffuse large b-cell lymphoma in the Korean population in 2017, based on the KCCR annual report data between 1999 and 2012. There are 19,659 cases, in the country was the most common subtype. South Korea has most number of people suffering from the diffuse large b-cell lymphoma.

Rise in prevalence of diffuse large b-cell lymphoma, surge in the geriatric population and increase in health care expenditure by governments drive the chemotherapy drugs in the region.

Diffuse large B-cell lymphoma (DLBCL) tends to grow quickly. Most often, the treatment is chemotherapy (chemo), usually with a regimen of 4 drugs known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), plus the monoclonal antibody rituximab (Rituxan). This regimen, known as R-CHOP, is most often given in cycles 3 weeks apart.  Thus growing use chemo drugs in the region is driving the growth of the market.

In South Korea, for patients who may not be able to tolerate more intensive chemo regimens, rituximab alone, rituximab with milder chemo drugs (such as chlorambucil or cyclophosphamide), or rituximab with lenalidomide will be given by the oncologist.

Moreover, the treatment of diffuse large b-cell lymphoma  in patients requires the use of different drugs like targeted therapy, chemotherapy and others. Furthermore, biological drugs on the basis of monoclonal antibodies (mAbs) have emerged as a preferred option to treat diffuse large b-cell lymphoma in the region.

Prescriptions for chemotherapy drugs can be filled through a number of channels such as clinics, specialty pharmacies, hospital pharmacies, physician’s office and other end user sources.

Increasing initiatives undertaken by key players is expected to fuel the growth of the market. In addition to this, an increase in pipeline candidates for the development of drugs for faster recovery of DLBCL is also driving the market growth during the forecast period. For instance, the launch of biosimilars of rituximab drug type which has obtained a huge market as monotherapy as well as combination therapy.

However, this type of lymphoma has enlarged B cell and cancer cells that are in extend out the pattern. Symptoms of large b-cell lymphoma therapeutics are weight loss, rise in temperature without any cause, heavy sweating, and others which are driving the growth of the market. Various tests are conducted for diagnosis of lymphomas such as blood tests, removal of lymph node, biopsy, and others that are positively influencing the market growth in the region.

Meanwhile emerging markets such as Malaysia, Thailand, Vietnam and Indonesia have large patient bases, fast-growing economies and increasing health care expenditure per capita that mean they will bring important future growth opportunities. 

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com